Publications:30
Igor Bado, PhD
About Me
Igor Bado, PhD, is an Assistant Professor in the Department of Oncological Sciences at the Icahn School of Medicine at Mount Sinai. Igor Bado obtained his PhD at the University of Houston and completed his postdoctoral studies at Baylor College of Medicine. Dr. Bado works on various mechanisms of breast cancer metastasis and therapeutic resistance. In his recent studies, he helped identify the FGFR/EZH2 axis as a central driver of epigenetic reprogramming in the early stage of bone metastasis. Dr. Bado received multiple awards and honors and his laboratory is NCI funded. His research focuses on understanding the interconnection between breast cancer metastases and their microenvironment using a multidisciplinary approach.
Visit the Bado Lab.
Language
English
Position
ASSISTANT PROFESSOR | Oncological Sciences
Research Topics
Breast Cancer, Cancer, Epigenetics, Metastasis
Multi-Disciplinary Training Areas
Cancer Biology [CAB]
Education
BSc, University of Ouagadougou
PhD, University of Houston
Postdoctoral, Baylor College of Medicine
Awards
2022
Biomedical Laureate
Icahn School of Medicine at Mount Sinai
2022
Dean’s Award of Excellence
Baylor College of Medicine
2022
NCI Pathway to Independence Award (K99/R00)
National Cancer Institute
2021
SPORE-Breast Center Career Enhancement Program Awardee
Baylor College of Medicine
Research
Dr. Bado studies how different tumor microenvironments crosstalk with cancer cells to promote survival, growth, and secondary spread to other organs. His goal is to understand epigenetic implications in cancer cell adaptation, intra-tumoral heterogeneity, and multi-organ metastasis. He believes that epigenetic factors -which modulate gene expression, are key players in the metastatic process and can be targeted to reprogram cancer cells toward improved therapeutic responses. Ultimately, he aims to identify therapeutic vulnerabilities for the long-term remission of metastatic diseases. He uses state-of-the-art approaches to dissect the mechanisms driving breast cancer metastasis from the early dissemination of CTCs to the formation of macro-metastases in advanced stages of the disease.
Publications
Selected Publications
- The MBCRC Advocate Researcher Program (MARP): connecting advocates and researchers as collaborative partners in cancer research. Hillary S. Andrews, Igor L. Bado, Amy Beumer, Isaac S. Chan, Janice Cowden, Debbie Denardi, Gloria V. Echeverria, Brooke L. Gates, Marybeth Gilliam, Christine Hodgdon, Adrian V. Lee, Joan Mancuso, Julia Maues, Steffi Oesterreich, Michael Papanicolaou, Katherine E. Pendleton, Bob Riter, Kelly Shanahan, Anh M. Tran-Huynh, Pavitra Viswanath, Stephanie Walker, Alana L. Welm, Michelle M. Williams, Garhett L. Wyatt, Josh Newby. npj Breast Cancer
- Single-cell profiling of bone metastasis ecosystems from multiple cancer types reveals convergent and divergent mechanisms of bone colonization. Fengshuo Liu, Yunfeng Ding, Zhan Xu, Xiaoxin Hao, Tianhong Pan, George Miles, Siyue Wang, Yi Hsuan Wu, Jun Liu, Igor L. Bado, Weijie Zhang, Ling Wu, Yang Gao, Liqun Yu, David G. Edwards, Hilda L. Chan, Sergio Aguirre, Michael Warren Dieffenbach, Elina Chen, Yichao Shen, Dane Hoffman, Luis Becerra Dominguez, Charlotte Helena Rivas, Xiang Chen, Hai Wang, Zbigniew Gugala, Robert L. Satcher, Xiang H.F. Zhang. Cell Genomics
- Tumor-derived arachidonic acid reprograms neutrophils to promote immune suppression and therapy resistance in triple-negative breast cancer. Liqun Yu, Keziah Liebenberg, Yichao Shen, Fengshuo Liu, Zhan Xu, Xiaoxin Hao, Ling Wu, Weijie Zhang, Hilda L. Chan, Bo Wei, Philip L. Lorenzi, Yang Gao, Igor Bado, Luis Becerra-Dominguez, Charlotte Helena Rivas, Sergio Aguirre, Bradley C. Pingel, Yi Hsuan Wu, Yunfeng Ding, Jun Liu, David G. Edwards, Livia S. Eberlin, Xiang H.F. Zhang. Immunity
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Bado during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Editorial Services
- Faseb Journal
- Springer Nature Limited
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.